文献速递肝病

非酒精性脂肪性肝炎 Medicare 患者疾病严重程度与医疗资源利用增加相关

Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

该回顾性观察性队列研究利用 Medicare 20% 样本数据,评估 2007-2015 年共 8 年间 NASH 严重程度对医疗资源利用和费用的影响。纳入 255,681 例 NAFLD/NASH 患者,按疾病进展分层分析。结果显示疾病越严重,年就诊次数和总费用越高,调整混杂后费用倍数显著增加。

要点

  • NASH 疾病越严重,年就诊次数和总费用越高。
  • 调整合并症后,肝硬化、肝移植和肝癌患者费用显著高于无进展者。
  • 预防 NASH 进展可能降低医疗资源利用和费用。

核心结论

  • NASH 尤其严重疾病对医疗资源利用和费用有重大影响。
  • 识别可能受益于预防进展干预的患者有助于减少医疗资源利用和费用。

研究设计与样本

  • 回顾性观察性队列研究,使用 Medicare 20% 样本数据,覆盖 2007-2015 年共 8 年。
  • 样本共 255,681 例 NAFLD/NASH 患者,其中无进展 185,407 例(72.5%),代偿性肝硬化 3,454 例(1.3%),失代偿性肝硬化 65,926 例(25.8%),肝移植 473 例(0.2%),肝细胞癌 421 例(0.2%)。

主要发现

  • 代偿性肝硬化或更严重肝病患者的糖尿病、高血压、高脂血症和心血管疾病合并症发生率显著高于无进展的 NAFLD/NASH 患者。
  • 全因年就诊平均次数从无进展的 32.1 次增至代偿性肝硬化的 37.3 次、失代偿性肝硬化的 59.8 次、肝移植的 74.1 次和肝细胞癌的 59.3 次(P < 0.05)。
  • 住院、门诊、医生和药房服务的年总费用从无进展的 19,908 美元增至肝移植的 129,276 美元(P < 0.05)。
  • 调整患者特征和合并症后,代偿性肝硬化、失代偿性肝硬化、肝移植和肝细胞癌患者的费用分别显著为无进展 NAFLD/NASH 患者的 1.19、3.15、5.02 和 3.33 倍。

临床怎么用

  • 临床应关注 NASH 疾病进展,尤其代偿性肝硬化及以上阶段,以预判医疗资源利用和费用增加。
  • 对 NASH 患者采取干预预防进展,可能有助于降低后续医疗资源利用和费用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: As the prevalence of nonalcoholic steatohepatitis (NASH) in the elderly population increases, healthcare resource utilization (HCRU) and costs are also predicted to rise substantially. METHODS: This retrospective, observational cohort study used the Medicare 20% sample data set to evaluate the impact of NASH severity on HCRU and costs over 8 years (2007-2015). The sample included 255,681 patients with nonalcoholic fatty liver disease (NAFLD)/NASH: 185,407 (72.5%) with NAFLD/NASH and no further progression to advanced liver disease, 3,454 (1.3%) with compensated cirrhosis (CC), 65,926 (25.8%) with decompensated cirrhosis (DCC), 473 (0.2%) with liver transplant (LT), and 421 (0.2%) with hepatocellular carcinoma (HCC). RESULTS: Rates of comorbid diabetes, hypertension, hyperlipidemia, and cardiovascular disease were significantly higher in patients with CC or more severe liver disease compared with NAFLD/NASH and no progression. The annual mean number of all-cause healthcare visits increased from 32.1 for NAFLD/NASH with no progression to 37.3 for CC, 59.8 for DCC, 74.1 for LT, and 59.3 for HCC (P < 0.05). Total annual costs for inpatient, outpatient, physician, and pharmacy services rose from $19,908 in NAFLD/NASH with no progression to $129,276 for LT (P < 0.05). Generalized linear model adjusted for patient characteristics and comorbidities revealed that costs were 1.19, 3.15, 5.02, and 3.33 times significantly higher in patients diagnosed with CC, DCC, LT, or HCC, respectively, compared with NAFLD/NASH and no progression. DISCUSSION: These results confirm the substantial impact of NASH, particularly more severe disease, on HCRU and costs and identify patients who may benefit from interventions to prevent progression and subsequently reduce HCRU and costs.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. C Gordon S, Fraysse J, Li S, et al. Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients. Am J Gastroenterol. 2020. PMID: 31833859. doi:10.14309/ajg.0000000000000484

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。